Last €20.93 EUR
Change Today +0.334 / 1.62%
Volume 763.6K
QIA On Other Exchanges
Symbol
Exchange
Xetra
NASDAQ GS
As of 1:49 PM 01/23/15 All times are local (Market data is delayed by at least 15 minutes).

qiagen n.v. (QIA) Snapshot

Open
€20.40
Previous Close
€20.60
Day High
€21.00
Day Low
€20.40
52 Week High
01/23/15 - €21.00
52 Week Low
04/15/14 - €14.03
Market Cap
5.0B
Average Volume 10 Days
550.7K
EPS TTM
€0.68
Shares Outstanding
239.7M
EX-Date
--
P/E TM
34.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for QIAGEN N.V. (QIA)

qiagen n.v. (QIA) Related Businessweek News

No Related Businessweek News Found

qiagen n.v. (QIA) Details

QIAGEN N.V. provides sample and assay technologies worldwide. It offers approximately consumable products, such as sample and assay kits, and automated instrumentation systems that empower customers to transform raw biological samples into molecular information. The company’s consumable products are used for plasmid deoxyribonucleic acid (DNA) purification, and ribonucleic acid purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. The company sells the digene HC2 HPV Test for high-risk strains of the human papillomavirus. It also offers co-development services for companion diagnostics, technology licensing and patent sales services, and custom services, including whole genome amplification, DNA sequencing, and non-cGMP DNA production on a contract basis. In addition, the company provides instrumentation systems that automate the use of sample and assay technologies into solutions for a range of laboratory needs enabling customers to perform nucleic acid sample preparation, assay setup, and target detection, as well as workflow solutions. Its automated systems include QIAsymphony, a modular system; Rotor-Gene Q, a rotary real-time PCR cycler system; PyroMark, a high-resolution detection platform; QIAcube, a sample processing instrument; QIAxcel for nucleic acid separation; and ESE-Quant tube scanners. The company serves molecular diagnostics laboratories; applied testing customers; pharmaceutical research and development groups, and academic researchers. It has a collaboration agreement with AstraZeneca PLC to co-develop and commercialize liquid biopsy-based companion diagnostic; and Astellas Pharma Inc. to develop and commercialize companion diagnostics for use in cancer and other diseases. QIAGEN N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands.

4,200 Employees
Last Reported Date: 10/31/14
Founded in 1986

qiagen n.v. (QIA) Top Compensated Officers

Chairman of Management Board, Chief Executive...
Total Annual Compensation: $1.5M
Chief Financial Officer, Managing Director an...
Total Annual Compensation: $639.5K
Compensation as of Fiscal Year 2013.

qiagen n.v. (QIA) Key Developments

Qiagen NV Revises Earnings Guidance for the Full-Year 2014 and Reaffirms Sales Guidance for the Fourth-Quarter of 2014

Qiagen NV revised earnings guidance for the full-year 2014 and reaffirmed sales guidance for the fourth-quarter of 2014. For full-year 2014, the company expects to achieve its previously announced guidance for adjusted diluted EPS of $1.08 CER (constant exchange rates), but for these results to be reduced to approximately $1.00 CER as a result of the restructuring charges. The company is reaffirming its guidance for adjusted net sales growth of approximately 4% CER for both the fourth quarter of 2014 as well as the full year.

QIAGEN Launches QuantiFERON®-TB Gold Plus

QIAGEN N.V. announced the CE product launch of QuantiFERON®-TB Gold Plus (QFT®-Plus), the fourth generation of the most accurate test for detecting tuberculosis (TB) infections. QFT-Plus builds on the legacy of QuantiFERON-TB Gold, which was the third-generation version of this important technology that has established itself as a cost-effective tool for TB infection testing with more than 20 million tests distributed worldwide since its initial launch. QFT-Plus, which was recently CE-IVD marked, is now being made available in Europe and other markets and will gradually replace the use of QuantiFERON-TB Gold, which achieved an important milestone with more than $100 million of annual sales in 2014 and becoming one of the large products within the QIAGEN portfolio. Among the many new features of QFT-Plus are: Improved technology that delivers even higher sensitivity (ability to correctly identify those patients with disease) and specificity (ability to correctly identify all patients without disease) in patients at great risk for TB infection, particularly individuals co-infected with HIV/TB and other immunocompromised patients. Advances to support research into the risk stratification of latent TB infections developing into active disease based on the first-time incorporation of CD8+ T cell response data, which provides valuable new information to researchers by measuring a broader range of immune response. Published scientific evidence underlines the future potential of CD8+ T cells in distinguishing active from latent TB, discerning recent vs. old infections, detecting TB in certain risk populations (such as HIV co-infection and young children), as well as assessing response to TB treatment. Workflow improvements that allow for even more efficient implementation, especially in large-scale TB screening programs. These include a single-tube blood collection option as well as the ongoing use of the unique "assay in collection tube" design that allows for immediate stimulation of the blood sample, which ensures no loss of T cell activity that is critical for obtaining accurate and reliable results. Further improvements to test reliability, consistency and performance designed to result in fewer indeterminate results and less requirements for retesting.

Qiagen NV Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:30 PM

Qiagen NV Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 02:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Peer M. Schatz, Chairman of Management Board, Chief Executive Officer and Managing Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QIA:GR €20.93 EUR +0.334

QIA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $114.70 USD -2.14
BioMerieux €97.50 EUR +1.41
Cepheid $55.02 USD -0.325
Myriad Genetics Inc $36.20 USD -0.58
PerkinElmer Inc $44.29 USD +0.45
View Industry Companies
 

Industry Analysis

QIA

Industry Average

Valuation QIA Industry Range
Price/Earnings 43.6x
Price/Sales 4.1x
Price/Book 2.0x
Price/Cash Flow 43.4x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QIAGEN N.V., please visit www.qiagen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.